Je was op zoek naar: exon (Engels - Maltees)

mutant kras (exon 2) population
popolazzjoni bi kras mutant (exon 2)

wild-type kras (exon 2) population
popolazzjoni bi kras tat-tip salvaġġ (exon 2)

braf mutations in exon 15 were found to be prognostic of worse outcome.
mutazzjonijiet ta’ braf f’exon 15 instab li kienu jbassru riżultat agħar.

clinically, activity in tumours harbouring the t790m mutation in exon 20 has also been shown.
klinikament, l-attività fit-tumuri li jkollhom il-mutazzjoni t790m f’exon 20 intweriet ukoll.

the ras mutant population consists of patients with known kras exon 2 mutations as well as additionally identified ras mutations.
il-popolazzjoni mutanti ras tikkonsisti minn pazjenti b’mutazzjonijiet kras exon 2 magħrufa kif ukoll b’mutazzjonijiet ras addizzjonali identifikati.

further post-hoc analyses on mutations on ras genes other than kras exon 2 have been evaluated.
analiżi post-hoc addizzjonali fuq mutazzjonijiet fuq ġeni ras minbarra dawk fuq kras exon 2 ġew evalwati.

patients with additional ras mutations beyond kras exon 2 were unlikely to benefit from the addition of panitumumab to folfiri and a detrimental effect was seen with the addition of panitumumab to folfox in these patients.
pazjenti b’mutazzjonijiet addizzjonali ta’ ras lil hinn minn kras exon 2 x’aktarx ma kienux jibbenefikaw miż-żieda ta’ panitumumab ma’ folfiri u f’dawn il-pazjenti kien osservat effett detrimentali biż-żieda ta’ panitumumab ma’ folfox.

limited non-clinical and/or clinical activity was observed in nsclc tumours with insertion mutations in exon 20.
attività limitata mhux klinika u/jew kliniċi ġiet osservata f’tumuri nsclc b’mutazzjonijiet ta’ inserzjoni f’exon 20.

activating mutations in jak2 (v617f or exon 12) are found in >95% of pv patients.
mutazzjonijiet ta’ attivazzjoni f’jak2 (v617f jew exon 12) jinstabu f’>95% tal-pazjenti b’pv.

a patient was considered to have a ret mutation if either an m918t mutation by the arms assay, or a ret mutation in any exons sequenced was present in the tumour.
pazjent kien meqjus li għandu mutazzjoni ret jekk il- mutazzjoni m918t permezz tal-essej arms fi kwalunkwe ekson kien preżenti fit-tumur.